Richard Goldberg MD
机构: Professor emeritus, West Virginia University
每年引用次数
引用次数
引用: 74,127
H-指数: 114
I10-指数 : 413
出版物: 900
A phase I study of sequential gemcitabine and MTA (LY231514) in patients with advanced malignancies
A. Adjei , C. Erlichman , H. Pitot , J. Sloan
European Journal of Cancer 35
1999
Phase I trial of sequential administration of tomudex and 5-iodo-2′-deoxyuridine (IdUrD)
E. Galanis , R. Goldberg , C. Erlichman , J. Sloan
European Journal of Cancer 35
1
1999
Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study #80303
D. Romanus , L. Archer , X. Wang , R. Goldberg
Journal of Clinical Oncology 25 9008 -9008
2007
A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303
D. Schrag , L. Archer , X. Wang , D. Romanus
Journal of Clinical Oncology 25 ( 18_suppl) 4524 -4524
13
2007
Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep
T. Bekaii-Saab , R. Goldberg
JNCI Journal of the National Cancer Institute 107 ( 2) dju439 -dju439
6
2015
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd)
E. Galanis , R. Goldberg , J. Reid , P. Atherton
Annals of Oncology 12 ( 5) 701 -707
4
2001
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.
E. Van Cutsem , M. Dicato , N. Arber , A. Benson
Annals of Oncology 17
22
2006
259 Patterns of failure after liver resectionin patients receiving FOLFOX4 for metastatic colorectal cancer (MCRC) limited to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study
S. Alberts , J. Donohue , M. Mahoney , W. Horvath
Ejc Supplements 1 ( 5)
5
2003
Phase III trial of adjuvant immunotherapy with MOAb 17–1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)
T. A. Colacchio , D. Niedzwiecki , C. Compton , R. Warren
Journal of Clinical Oncology 22 3522 -3522
17
2004
Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor
TerrenceL. Cascino , MichaelH. Veeder , JanC. Buckner , JudithR. O'Fallon
Journal of Neuro-oncology 30 ( 3) 243 -246
11
1996
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
RichardM. Goldberg , Sharlene Gill
Cancer Chemotherapy and Pharmacology 54 ( 1)
29
2004
Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy
Alan P Venook , Steven A Curley , Kenneth K Tanabe , RM GoldbergU
UpToDate
1
2022
A flexible design for multiple armed screening trials
Daniel J SARGENT , Richard M GOLDBERG
Statistics in medicine 21 ( 4) 625 -627
1
2002
Clinical cases
AE Pinto , S Andre , T Pereira , S Nobrega
2001
INFUSION PORT MARKER
RM GOLDBERG
JOURNAL OF CLINICAL ONCOLOGY 2 ( 11) 1305 -1305
1984
FACTORS INFLUENCING TEACHING EFFECTIVENESS
LS JEWETT , LW GREENBERG , RM GOLDBERG
AMERICAN JOURNAL OF DISEASES OF CHILDREN 137 ( 6) 544 -544
1983
Irinotecan plus Fluorouracil and Leucovorin
CHARIES ERI ICHMAN , RICHARD M GOLDBERG
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Howard McLeod , Daniel J. Sargent , Richard M. Goldberg
Transactions of the American Clinical and Climatological Association 121 21
1
2010
The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer
Charles Erlichman , Daniel J. Sargent , Richard M. Goldberg
Humana Press, Totowa, NJ 191 -198
2003
Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group.
Charles L. Loprinzi , John C. Michalak , Patrick A. Burch , Neil M. Ellison
Seminars in Oncology 17 ( 6) 8 -12
18
1990